PURPOSE OF REVIEW: Mammalian bombesin-related peptides, gastrin-releasing peptide and neuromedin B actions are mediated by two receptors (BB1-receptor, BB2-receptor), which are closely related to the orphan receptor BRS-3 (BB3-receptor). The purpose of this review is to highlight advances in the understanding of these peptides in physiology/disease states. RECENT FINDINGS: Pharmacologic/receptor-knockout studies show involvement of these receptors in a number of new processes/diseases. Neuromedin B/BB1-receptor is an important physiological regulator of pituitary-thyroid function; in mediating behavior, especially feas/anxiety; in mediating satiety through different cascades than gastrin-releasing peptide/BB2 receptors and for its autocrine tumor-growth effects. Gastrin-releasing peptide/BB2-receptor plays important roles in mediating signals for pruritus, lung development/injury, small intestinal mucosal defense, and central nervous system processes such as learning/memory. The signaling mechanisms of its potent growth effects are being elucidated and their possible therapeutic targets identified. BB3-receptor knockout mice provided insights for their obesity/glucose intolerance and demonstrated that this receptor may be important in the lung response to injury, tumor growth and gastrointestinal motility. Each receptor is frequently overexpressed in human tumors and has potent growth effects. This effect is being explored to develop new antitumor treatments, such as bombesin-receptor ligands conjugated to cytotoxic agents. SUMMARY: This receptor family is involved in an increasing number of central nervous system/peripheral processes physiologically and in disease states, and increased understanding of its role may lead to novel treatments.
PURPOSE OF REVIEW: Mammalianbombesin-related peptides, gastrin-releasing peptide and neuromedin B actions are mediated by two receptors (BB1-receptor, BB2-receptor), which are closely related to the orphan receptor BRS-3 (BB3-receptor). The purpose of this review is to highlight advances in the understanding of these peptides in physiology/disease states. RECENT FINDINGS: Pharmacologic/receptor-knockout studies show involvement of these receptors in a number of new processes/diseases. Neuromedin B/BB1-receptor is an important physiological regulator of pituitary-thyroid function; in mediating behavior, especially feas/anxiety; in mediating satiety through different cascades than gastrin-releasing peptide/BB2 receptors and for its autocrine tumor-growth effects. Gastrin-releasing peptide/BB2-receptor plays important roles in mediating signals for pruritus, lung development/injury, small intestinal mucosal defense, and central nervous system processes such as learning/memory. The signaling mechanisms of its potent growth effects are being elucidated and their possible therapeutic targets identified. BB3-receptor knockout mice provided insights for their obesity/glucose intolerance and demonstrated that this receptor may be important in the lung response to injury, tumor growth and gastrointestinal motility. Each receptor is frequently overexpressed in humantumors and has potent growth effects. This effect is being explored to develop new antitumor treatments, such as bombesin-receptor ligands conjugated to cytotoxic agents. SUMMARY: This receptor family is involved in an increasing number of central nervous system/peripheral processes physiologically and in disease states, and increased understanding of its role may lead to novel treatments.
Authors: Qing Zhang; Neil E Bhola; Vivian Wai Yan Lui; Doris R Siwak; Sufi M Thomas; Christopher T Gubish; Jill M Siegfried; Gordon B Mills; Dong Shin; Jennifer Rubin Grandis Journal: Mol Cancer Ther Date: 2007-04 Impact factor: 6.261
Authors: Adam F Prasanphanich; Prasant K Nanda; Tammy L Rold; Lixin Ma; Michael R Lewis; Jered C Garrison; Timothy J Hoffman; Gary L Sieckman; Said D Figueroa; Charles J Smith Journal: Proc Natl Acad Sci U S A Date: 2007-07-12 Impact factor: 11.205
Authors: W A P Breeman; D J Kwekkeboom; E de Blois; M de Jong; T J Visser; E P Krenning Journal: Anticancer Agents Med Chem Date: 2007-05 Impact factor: 2.505
Authors: Xuwan Liu; Diane L Carlisle; Michelle C Swick; Autumn Gaither-Davis; Jennifer R Grandis; Jill M Siegfried Journal: Exp Cell Res Date: 2007-02-03 Impact factor: 3.905
Authors: Veronica Sancho; Terry W Moody; Samuel A Mantey; Alessia Di Florio; Hirotsugu Uehara; David H Coy; Robert T Jensen Journal: Peptides Date: 2010-05-12 Impact factor: 3.750
Authors: Wael R Abd-Elgaliel; Fabio Gallazzi; Jered C Garrison; Tammy L Rold; Gary L Sieckman; Said Daibes Figueroa; Timothy J Hoffman; Susan Z Lever Journal: Bioconjug Chem Date: 2008-09-23 Impact factor: 4.774
Authors: Irene Ramos-Álvarez; Paola Moreno; Samuel A Mantey; Taichi Nakamura; Bernardo Nuche-Berenguer; Terry W Moody; David H Coy; Robert T Jensen Journal: Peptides Date: 2015-05-11 Impact factor: 3.750
Authors: Hirotsugu Uehara; Nieves González; Veronica Sancho; Samuel A Mantey; Bernardo Nuche-Berenguer; Tapas Pradhan; David H Coy; Robert T Jensen Journal: Peptides Date: 2011-06-28 Impact factor: 3.750
Authors: Hirotsugu Uehara; Simon J Hocart; Nieves González; Samuel A Mantey; Tomoo Nakagawa; Tatsuro Katsuno; David H Coy; Robert T Jensen Journal: Biochem Pharmacol Date: 2012-07-22 Impact factor: 5.858